• Leveraging GSK126: A Selective EZH2 Inhibitor for Epigene...

  2025-10-23

  GSK126, a potent and selective EZH2/PRC2 inhibitor, empowers researchers to dissect cancer epigenetics with precision, especially in lymphoma and solid tumors harboring EZH2 mutations. This guide integrates advanced workflows, troubleshooting strategies, and emerging applications—distilling both mechanistic and translational insights for oncology drug development and beyond.

• GSK126: Selective EZH2 Inhibitor Transforming Cancer Epig...

  2025-10-22

  GSK126 is a best-in-class selective EZH2/PRC2 inhibitor, delivering robust and precise disruption of cancer-driving epigenetic silencing. Its superior potency against EZH2-mutant tumors and compatibility with advanced experimental models empower researchers to decode PRC2 signaling and accelerate oncology drug development.

• Advancing Native Protein Analysis: Innovations with the B...

  2025-10-21

  Discover how the Basic Protein Native PAGE Gel Preparation and Electrophoresis Kit (PI ≤ 7.0) revolutionizes native polyacrylamide gel electrophoresis for proteins with PI ≤ 7.0, preserving activity for advanced biochemical analysis. This article uniquely explores mechanistic innovations and translational opportunities in protein research.

408 records 28/28 page Previous First page 上5页 262728